#268: Emerging Biopharma Therapeutic Modalities: Scientific and Policy Implications
Chair
Vice President, Head of Vaccines & Microbiome, Global Regulatory Affairs, Janssen Pharmaceuticals (johnson & Johnson)
Adam Hacker was appointed VP Head of Vaccines & microbiome for Global Regulatory Affairs at Janssen Pharmaceuticals (Johnson & Johnson company) in June 2015. As Head of Vaccines he is responsible for driving regulatory strategy with a focus on the accelerated development of Janssen’s...
Read More →
Speakers
Acting Chief Scientist, Office of the Chief Scientist, OC, FDA
Dr. Luciana Borio is FDA’s acting chief scientist. In this capacity, she is responsible for leading and coordinating FDA's cross-cutting scientific and public health efforts. The Office of the Chief Scientist works closely with FDA’s product centers, providing strategic leadership...
Read More →
Senior Vice President, Regulatory Science, bluebird bio, Inc.
Anne-Virginie joined bluebird bio in 2011 to lead global regulatory strategy and create innovative pathways to accelerate the development of bluebird bio’s gene therapy products. Previously, AV was an Executive Director at Voisin Consulting, leading rare diseases, oncology, and...
Read More →
Tuesday June 28, 2016 4:00pm - 5:15pm EDT
201C
Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA